AIVIS Co., Ltd. (CEO Daehong Lee/AIVIS), a company specializing in AI-based pathology analysis solutions, announced on the 1st that it will participate in the digital pathology conference 'Pathology Visions 2025' to be held in San Diego, USA in October, where it will present the latest AI diagnostic assistance solutions and research results, and strengthen its global network.
Hosted by the Digital Pathology Association (DPA), Pathology Vision is a prestigious conference where pathology experts and industry leaders from around the world gather to share cutting-edge technologies and research findings. Avis plans to showcase the technological excellence of its flagship products and expand its global partnerships at this conference.
In particular, Avis will unveil for the first time, through this conference poster session, a large-scale benchmark dataset for quantitative analysis of breast cancer Ki-67, called "QuoCa (QuaCCa-BRS Ki-67). "QuoCa" is a meticulously manually annotated cell-level dataset encompassing various histological patterns and cell types. An Avis representative stated, "This establishes an important foundation for verifying and standardizing the objective performance of AI pathology analysis models. This is expected to increase the reliability of AI diagnostic solutions, contribute to patient safety, and accelerate the clinical adoption of automated solutions."
In addition, they are actively promoting the excellence of their flagship product, the AI-based biomarker quantitative analysis solution, 'Qanti® IHC'. 'Qanti® IHC' is a software that quantitatively analyzes the expression of major biomarkers such as ER, PR, HER2, and Ki-67 in IHC tissue pathology images to assist pathologists in making diagnoses. In particular, they have recently proven their technological prowess in the field of precision medicine by collaborating with the global pharmaceutical company AstraZeneca to "build an AI-based HER2 diagnostic ecosystem." At this conference, Avis plans to highlight the high accuracy (Pearson correlation coefficient = 0.979) of 'Qanti IHC' verified through the 'Quokka' dataset and seek cooperation with global pharmaceutical and medical device companies.
We are also introducing the "Qanti® Micro" solution, which dramatically improves accessibility in the field of digital pathology. "Qanti® Micro" is an innovative product that enables immediate biomarker analysis using images captured with a camera attached to a standard optical microscope, eliminating the need for expensive, large slide scanners. This allows small and medium-sized hospitals and research institutes, which struggle to implement digital pathology systems, to perform AI-based quantitative analysis at a reasonable cost, significantly improving diagnostic efficiency and convenience.
Lee Dae-hong, CEO of Avis, said, “Participating in Pathology Visions 2025 is an important opportunity to showcase Avis’ innovative technology to the world,” and expressed his ambition by saying, “Through the announcement of the ‘Quokka’ dataset, we will present a standard in the field of AI pathology diagnosis, and based on our collaboration with AstraZeneca and the competitiveness of the ‘Quanti’ product line, we will further accelerate our entry into the global market.”
- See more related articles
You must be logged in to post a comment.